logo
Share SHARE
FONT-SIZE Plus   Neg

FDA Approves Teva Pharma's NDA For Quartette Contraceptives - Quick Facts

Teva Pharmaceutical Industries Ltd. (TEVA) announced the FDA has approved Quartette tablets for the prevention of pregnancy. The approval was based on a development program that included results from Phase I, Phase II and Phase III clinical trials. The Phase III clinical trial, which involved more than 3,000 women, found that Quartette was 97 percent effective at preventing pregnancy, the company said.

Quartette features a 91-day oral regimen, whereby the dose of estrogen increases at three distinct points over the first 84 days and the amount of progestin remains consistent; this is followed by seven days of 10 mcg of ethinyl estradiol.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
HSBC is reportedly laying off about 100 of its senior investment bankers worldwide, as the banking giant strives to curb operating costs. According to reports, the London-headquartered bank will eliminate managing director and director level employees at the Global Banking and Markets division, as... Samsung Electronics Co., Ltd. (SMSN.L, SSNNF.OB, SSNLF.OB) will reportedly blame faulty batteries for last year's Galaxy Note 7 fiasco. According to a Wall Street Journal report, Samsung's investigation of Galaxy Note 7 smartphones found that some batteries were irregularly sized while others had... Federal investigators have closed their probe of a fatal crash that involved a Tesla Motors Inc. car eight months ago. The regulators said they have found no safety defects in the vehicle's automated driving system and that Tesla's Autopilot-enabled vehicles did not need to be recalled.
comments powered by Disqus
Follow RTT